Matinas BioPharma Holdings, Inc. (MTNB) Balance Sheet
MTNB balance sheet, 2025
December 31, 2025 · U.S. dollars$7.2M assets = $2.4M liabilities + $4.8M equity
Both columns are drawn to the same scale: what MTNB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
MTNB financial health
Descriptive bands, not a rating. Fiscal 2025.
MTNB balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $9.8M2016 | $7.2M2025 | −3.4%/yr | |
| Total liabilities | $2.7M2016 | $2.4M2025 | −1.3%/yr | |
| Shareholders’ equity | $7.1M2016 | $4.8M2025 | −4.3%/yr | |
| Cash & short-term investments | $4.1M2016 | $4.0M2025 | −0.3%/yr | |
| Total debt | $144,4322016 | $1.4M2025 | +28.2%/yr | |
| Net cash (debt) | $4.0M2016 | $2.6M2025 | −$1.3M | |
| Working capital | $3.1M2016 | $2.6M2025 | −$508,695 | |
| Book value per share | $242.762020 | $13.232025 | −44.1%/yr | |
| Current ratio | 3.162016 | 2.792025 | −0.37 | |
| Debt / equity | 0.022016 | 0.282025 | +0.26 | |
| Shares outstanding | 263K2020 | 365K2025 | +6.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MTNB assets
MTNB liabilities and equity
MTNB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
MTNB balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $4.0M | $7.3M | $13.8M | $28.8M | $49.6M | $58.7M | $27.8M | $12.4M | $7.3M | $4.1M |
| Cash & equivalents | $4.0M | $7.3M | $4.8M | $6.9M | $21.0M | $12.4M | $22.2M | $12.4M | $7.3M | $4.1M |
| Short-term investments | — | $0 | $9.0M | $21.9M | $28.6M | $46.2M | $5.6M | — | $155,000 | $156,000 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $650,000 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $76,000 | $741,000 | $1.8M | $5.7M | $1.4M | $2.2M | $2.1M | $638,646 | $657,463 | $460,037 |
| Total current assets | $4.1M | $8.0M | $15.5M | $34.5M | $51.0M | $61.6M | $29.9M | $13.1M | $8.0M | $4.6M |
| Property, plant & equipment (net) | $673,000 | $2.2M | $5.0M | $5.7M | $5.8M | $4.9M | $5.6M | $2.0M | $1.6M | $356,000 |
| Goodwill & intangible assets | $2.3M | $2.3M | $4.4M | $4.4M | $4.4M | $4.4M | $4.4M | $4.4M | $4.4M | $4.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $200,000 | $200,000 | $200,000 | $34.2M | $200,000 | $199,950 | $336,000 | $460,893 | $535,857 | $540,988 |
| Total assets | $7.2M | $12.6M | $25.1M | $78.9M | $61.3M | $71.0M | $40.2M | $19.9M | $14.4M | $9.8M |
| Liabilities | ||||||||||
| Accounts payable | $315,000 | $95,000 | $514,000 | $618,000 | $937,000 | $349,941 | $679,310 | $295,652 | $582,867 | $475,602 |
| Short-term debt | $696,000 | $766,000 | $661,000 | $569,000 | $560,000 | $422,351 | $478,414 | $283,087 | $197,211 | $127,982 |
| Deferred revenue | — | — | — | $809,000 | $33,000 | $643,000 | $100,000 | −$83,245 | $29,937 | −$9,936 |
| Total current liabilities | $1.5M | $2.7M | $2.6M | $4.3M | $4.3M | $3.6M | $3.1M | $2.8M | $2.2M | $1.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $54,510 | $107,660 | $67,680 | $16,450 |
| Lease obligations | $1.4M | $2.9M | $3.6M | $4.1M | $4.7M | $3.8M | $4.2M | $190,901 | $94,658 | $26,382 |
| Other long-term liabilities | $915,000 | $2.4M | $3.2M | $37.9M | $4.5M | $3.7M | $4.0M | $853,965 | $1.4M | $1.2M |
| Total liabilities | $2.4M | $5.1M | $5.9M | $42.2M | $8.8M | $7.2M | $7.2M | $3.8M | $3.7M | $2.7M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $22,000 | $22,000 | $22,000 | $20,010 | $16,000 | $11,329 | $9,335 | $5,817 |
| Retained earnings (deficit) | −$210.8M | −$199.8M | −$175.6M | −$152.6M | −$131.6M | −$107.5M | −$84.4M | −$65.9M | −$51.3M | −$35.2M |
| Accumulated other comprehensive income | — | — | −$221,000 | −$824,000 | −$145,000 | $228,172 | −$1,000 | −$439,000 | $0 | −$140,000 |
| Total shareholders' equity | $4.8M | $7.6M | $19.2M | $36.6M | $52.5M | $63.7M | $33.1M | $16.1M | $10.7M | $7.1M |
| Key figures | ||||||||||
| Total debt | $1.4M | $2.9M | $3.6M | $4.1M | $4.7M | $3.8M | $4.2M | $390,747 | $264,894 | $144,432 |
| Net cash (debt) | $2.6M | $4.4M | $10.2M | $24.7M | $44.9M | $54.9M | $23.5M | $12.1M | $7.0M | $4.0M |
| Working capital | $2.6M | $5.4M | $12.9M | $30.2M | $46.6M | $58.0M | $26.8M | $10.2M | $5.7M | $3.1M |
| Tangible book value | $2.6M | $5.3M | $14.9M | $32.3M | $48.1M | $59.4M | $28.7M | $11.8M | $6.3M | $2.8M |
| Book value per share | $13.23 | $23.40 | $66.44 | $126.74 | $187.32 | $242.76 | — | — | — | — |
| Shares outstanding | 365K | 324K | 290K | 289K | 280K | 263K | — | — | — | — |
| Current ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 |
| Quick ratio | 2.73 | 2.73 | 5.25 | 6.72 | 11.41 | 16.63 | 8.97 | 4.38 | 3.28 | 2.84 |
| Debt / equity | 0.28 | 0.38 | 0.18 | 0.11 | 0.09 | 0.06 | 0.13 | 0.02 | 0.02 | 0.02 |
| Equity / assets | 67.0% | 60.0% | 76.7% | 46.5% | 85.6% | 89.8% | 82.1% | 80.9% | 74.1% | 72.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $761,000 | $2.4M | $4.0M | $5.4M | $6.5M | $6.9M | $7.3M | $10.8M | $14.3M | $8.1M | $13.8M | $18.2M |
| Cash & equivalents | $761,000 | $2.4M | $4.0M | $5.4M | $6.5M | $6.9M | $7.3M | $10.3M | $4.2M | $1.1M | $4.8M | $6.4M |
| Short-term investments | — | — | — | — | — | — | $0 | $500,000 | $10.1M | $7.0M | $9.0M | $11.8M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $382,000 | $367,000 | $76,000 | $218,000 | $743,000 | $623,000 | $741,000 | $946,000 | $972,000 | $2.2M | $1.8M | $1.8M |
| Total current assets | $1.1M | $2.8M | $4.1M | $5.7M | $7.3M | $7.5M | $8.0M | $11.7M | $15.3M | $10.3M | $15.5M | $20.0M |
| Property, plant & equipment (net) | $9,000 | $599,000 | $673,000 | $1.4M | $1.6M | $2.0M | $2.2M | $4.3M | $4.5M | $4.8M | $5.0M | $5.2M |
| Goodwill & intangible assets | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $4.4M | $4.4M | $4.4M | $4.4M | $4.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $200,000 | $200,000 | $426,000 | $270,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 |
| Total assets | $3.4M | $5.9M | $7.2M | $9.7M | $11.4M | $12.0M | $12.6M | $20.6M | $24.4M | $19.6M | $25.1M | $29.8M |
| Liabilities | ||||||||||||
| Accounts payable | $845,000 | $712,000 | $315,000 | $80,000 | $167,000 | $282,000 | $95,000 | $349,000 | $238,000 | $473,000 | $514,000 | $835,000 |
| Short-term debt | $1,000 | $720,000 | $696,000 | $851,000 | $822,000 | $794,000 | — | $738,000 | $712,000 | $686,000 | $661,000 | $637,000 |
| Total current liabilities | $1.4M | $2.1M | $1.5M | $1.5M | $1.8M | $2.3M | $2.7M | $2.1M | $2.4M | $2.0M | $2.6M | $3.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $6,000 | $1.2M | $1.4M | $2.3M | $2.5M | $2.7M | $2.9M | $3.1M | $3.2M | $3.4M | $3.6M | $3.7M |
| Other long-term liabilities | $262,000 | $726,000 | $915,000 | $1.7M | $2.0M | $3.5M | $2.4M | $2.7M | $2.9M | $3.1M | $3.2M | $3.4M |
| Total liabilities | $1.6M | $2.9M | $2.4M | $3.2M | $3.7M | $5.8M | $5.1M | $4.8M | $5.3M | $5.1M | $5.9M | $6.6M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | — | $1,000 | $25,000 | $22,000 | $22,000 | $22,000 |
| Retained earnings (deficit) | −$214.0M | −$212.7M | −$210.8M | −$208.9M | −$206.7M | −$201.5M | −$199.8M | −$191.4M | −$187.1M | −$181.4M | −$175.6M | −$170.3M |
| Accumulated other comprehensive income | — | $0 | — | — | — | — | — | $0 | −$51,000 | −$134,000 | −$221,000 | −$359,000 |
| Total shareholders' equity | $1.8M | $3.0M | $4.8M | $6.5M | $7.7M | $6.3M | $7.6M | $15.8M | $19.1M | $14.6M | $19.2M | $23.1M |
| Key figures | ||||||||||||
| Total debt | $6,000 | $1.2M | $1.4M | $2.3M | $2.5M | $2.7M | — | $3.1M | $3.2M | $3.4M | $3.6M | $3.7M |
| Net cash (debt) | $755,000 | $1.3M | $2.6M | $3.1M | $4.0M | $4.2M | — | $7.7M | $11.1M | $4.7M | $10.2M | $14.5M |
| Working capital | −$207,000 | $689,000 | $2.6M | $4.2M | $5.5M | $5.3M | $5.4M | $9.6M | $12.9M | $8.3M | $12.9M | $16.8M |
| Tangible book value | −$460,000 | $762,000 | $2.6M | $4.2M | $5.4M | $4.0M | $5.3M | $11.4M | $14.8M | $10.2M | $14.9M | $18.8M |
| Book value per share | $4.21 | $7.08 | $13.23 | $17.83 | $22.63 | $18.49 | — | $46.98 | $57.46 | $50.23 | $66.44 | $79.91 |
| Shares outstanding | 427K | 427K | 365K | 362K | 339K | 339K | — | 336K | 332K | 290K | 290K | 290K |
| Current ratio | 0.85 | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 | 6.19 |
| Quick ratio | 0.56 | 1.15 | 2.73 | 3.64 | 3.66 | 3.07 | 2.73 | 5.08 | 5.98 | 4.06 | 5.25 | 5.64 |
| Debt / equity | 0.00 | 0.39 | 0.28 | 0.36 | 0.33 | 0.43 | — | 0.19 | 0.17 | 0.23 | 0.18 | 0.16 |
| Equity / assets | 52.8% | 51.4% | 67.0% | 66.6% | 67.2% | 52.1% | 60.0% | 76.7% | 78.4% | 74.2% | 76.7% | 77.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
MTNB financial position
At the end of fiscal 2025 (December 31, 2025), Matinas BioPharma had total assets of $7.2 million (down 43.0% from a year earlier), total liabilities of $2.4 million and shareholders' equity of $4.8 million. It held $4.0 million in cash and short-term investments against $1.4 million of debt, a net cash position of $2.6 million. Its current ratio was 2.79. In the latest quarter (ended June 30, 2026) total assets were $3.4 million and equity $1.8 million.
Related: MTNB income statement, MTNB cash flow statement, MTNB key metrics. See the MTNB stock overview for the latest quote and news.
MTNB balance sheet FAQ
What are Matinas BioPharma's total assets?
Matinas BioPharma reported total assets of $7.2 million at the end of fiscal 2025 (December 31, 2025), compared with $12.6 million a year earlier.
How much debt does Matinas BioPharma have?
Matinas BioPharma had $1.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.28.
How much cash does Matinas BioPharma have?
Matinas BioPharma held $4.0 million in cash and short-term investments at the end of fiscal 2025; with $1.4 million of debt that is net cash of $2.6 million.
What is Matinas BioPharma's book value?
Matinas BioPharma's shareholders' equity (book value) was $4.8 million at the end of fiscal 2025, or $13.23 per share.
What is Matinas BioPharma's current ratio?
Matinas BioPharma had current assets of $4.1 million and current liabilities of $1.5 million, a current ratio of 2.79 (it can cover its short-term obligations).
How much goodwill does Matinas BioPharma have?
Matinas BioPharma carried $2.3 million of goodwill and intangible assets, 31.4% of total assets, at the end of fiscal 2025.